What type of study is this?

This is a Cohort Study study (also classified as: Experimental Study).

September 17, 2025

Metabolic CEST MR imaging of glucosamine uptake in brain tumors

Key Points

Glucosamine uptake in brain tumors shows significant enhancement compared to healthy tissue.
MTRasym analysis revealed higher signal at tumor sites, with a P-value less than 0.05 denoting statistical significance.
CEST MRI scans were conducted on tumor-bearing mice before and after glucosamine injection to evaluate uptake.
This initial study highlights glucosamine’s low toxicity and possible role in brain tumor imaging but requires further validation.

Abstract

Motivation: The CEST signal of glucosamine (GlcN), a non-toxic food supplement was previously demonstrated in breast tumors and mouse brains. Goal(s): To investigate GlcN uptake and efficacy in detecting brain tumors. Approach: CEST MRI scans (7T) were performed in tumor-bearing mice (n=6) before and after GlcN injection. Data were analyzed using the magnetization transfer ratio asymmetry (MTRasym) metric. Results: Tumor regions presented signal enhancement compared to the contralateral tissue. The area under the MTRasym curve (1-2.2 ppm) was significantly higher at the tumor (P<0.05). Impact: This is the first study that examines the use of GlcN for brain tumor imaging. Given its low toxicity and transport capabilities across the blood-brain barrier (BBB), GlcN may be used as a nonmetallic contrast agent for evaluating brain malignancies.

AI에게 질문

Bookmark